Ajanta Pharma, an India-based specialty pharmaceutical firm employing approximately 11,000 people, is understood to be eyeing a manufacturing operation in Ireland to support international growth and strengthen market access in the United States and Europe. The company currently operates seven manufacturing facilities in India, six producing finished formulations and one dedicated to active pharmaceutical ingredients, alongside an R&D centre in Mumbai with almost 1,000 staff.

The company generated revenue equivalent to €448 million in its last financial year, with EBITDA of €121.6 million, up 10% and 7% respectively from the prior year. Free cash flow reached €67 million. Its branded generics segment accounted for 74% of revenue, while its US business contributed 23%, highlighting the importance of international markets in its growth strategy.

A company spokesperson said: “We do not have any comments to offer at this stage,” regarding the proposed Ireland operation. Nevertheless, the move could take advantage of trade exemptions that shield Irish pharmaceutical exports from US tariffs, providing strategic cost benefits.

Ajanta’s portfolio spans cardiology, anti-diabetes, ophthalmology, dermatology, antibiotics, anti-malarial, pain management, respiratory, gynaecology, paediatric, and general health products. The company supplies over 30 countries and maintains a strong presence in India and emerging markets, particularly Africa.

In its second-quarter results released last November, Ajanta reported a 14% increase in revenue and a 20% rise in profit after tax, demonstrating resilient margins despite rising expenses. A manufacturing facility in Ireland would enable Ajanta to expand production capacity, enhance supply chain efficiency, and support export growth in Europe and the US.

Explore how Ajanta Pharma’s potential Irish manufacturing operation could reshape its global production and export strategy.

(Photo Credits to Getty)